Apitegromab
Spinal Muscular Atrophy (Types 2 & 3)
Key Facts
About Scholar Rock Holding
Scholar Rock is a clinical-stage biopharmaceutical company founded on a paradigm-shifting scientific strategy: targeting the latent, inactive forms of growth factors, particularly within the TGFβ superfamily, to achieve precise, localized therapeutic effects. The company's most advanced asset, apitegromab, has demonstrated promising Phase 3 results in spinal muscular atrophy (SMA) and is positioned as a potential first-in-class muscle-targeted therapy. Supported by a robust proprietary platform and a strong financial position, Scholar Rock's strategy extends beyond neuromuscular diseases into cardiometabolic disorders and immuno-oncology, aiming to build a diversified portfolio of novel biologics.
View full company profileAbout Scholar Rock Holding
Scholar Rock is a clinical-stage biopharmaceutical company founded on a paradigm-shifting scientific strategy: targeting the latent, inactive forms of growth factors, particularly within the TGFβ superfamily, to achieve precise, localized therapeutic effects. The company's most advanced asset, apitegromab, has demonstrated promising Phase 3 results in spinal muscular atrophy (SMA) and is positioned as a potential first-in-class muscle-targeted therapy. Supported by a robust proprietary platform and a strong financial position, Scholar Rock's strategy extends beyond neuromuscular diseases into cardiometabolic disorders and immuno-oncology, aiming to build a diversified portfolio of novel biologics.
View full company profileOther Spinal Muscular Atrophy (Types 2 & 3) Drugs
| Drug | Company | Phase |
|---|---|---|
| apitegromab (SRK-015) | Scholar Rock | Phase 3 |